Clinical Trial: Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks
Study Status: Completed
Recruit Status: Unknown status
Study Type: Observational
Official Title: Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.
Brief Summary: Assessment of treatment success and quality of life in patients with actinic keratoses under therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.
Detailed Summary: Non-interventional (observational) study (NIS), non-controlled, prospective cohort study.
Sponsor: LEO Pharma
Current Primary Outcome:
- Actinic keratosis [ Time Frame: 8 weeks ]Documentation of the course of actinic keratoses and skin findings during ambulant routine use of Picato®
- Quality of life [ Time Frame: 8 weeks ]Patient' s quality of life during ambulant routine use of Picato®
- Dosage of Picato® [ Time Frame: 8 weeks ]Prescribed and applied dosages and adherence during ambulant routine use of Picato®
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: LEO Pharma
Dates:
Date Received: March 12, 2014
Date Started: July 2013
Date Completion: April 2014
Last Updated: March 17, 2014
Last Verified: March 2014